Key result
Intravenous administration of AdmCTLA4Ig provided optimal immunosuppression and prolonged stable transgene expression in muscle for at least 2 months compared to intramuscular administration.
Population
Mice receiving an intramuscular injection of an adenoviral vector encoding enhanced green fluorescent protein
Comparison
AdmCTLA4Ig administered intravenously or in the… vs AdmCTLA4Ig administered intramuscularly (i.m.)
Design
Preclinical
Follow-up
Up to 2 months
Authors
Loading...
IV AdmCTLA4Ig may optimize muscle gene transfer in models; leaves open human translation and requires prospective trials.
Intravenous administration of AdmCTLA4Ig provides optimal immunosuppression to prolong adenoviral vector-mediated transgene expression in skeletal muscle.
Jiang et al. (2002) studied Skeletal muscle gene therapy. AdmCTLA4Ig (intravenous or footpad administration) vs. Intramuscular administration of AdmCTLA4Ig was evaluated on EGFP expression in muscle and serum levels of CTLA4Ig. Intravenous administration of AdmCTLA4Ig provided optimal immunosuppression and prolonged stable transgene expression in muscle for at least 2 months compared to intramuscular administration.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: